This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Delivered as Hybrid Event from 15-19 November 2021
Live In-Person Conference Delivered 15-17 NovemberSheraton Airport Brussels, Belgium

Tae-Won Kim, PhD
Executive Director Toxicology at Ionis Pharmaceuticals


Tae-Won Kim received his Ph.D in the Department of Environmental and Molecular Toxicology from North Carolina State University at Raleigh in 1996, studying skin carcinogenesis model.  Following his Ph.D., he was a post-doctoral fellow at University of California, San Francisco until 1997.  His postgraduate training included research in the areas of tumor metastasis and oral carcinogenesis.  He then joined SUGEN as a toxicologist in the Department of PK and Toxicology.  Along with a team of dedicated colleagues, he was a Group Leader Toxicologist for SUTEN project until 2001.  Then, he joined Ionis Pharmaceuticals Inc. until now. He is currently, Executive Director of Toxicology and has participated in the development of Kynamro, Inotersen, Volanesorsen and multiple 2¢-MOE modified phosphorothioate antisense oligonucleotides with/without covalently bound to triantenary N-acetyl galactosamine (GalNAc3) conjugate.

Agenda Sessions

  • Nonclinical Safety Assessment for GalNac3-Conjugated TTR ASO and Inotersen

    On Demand
  • Safety Issues Related to Chemically Modified Oligos and Conjugates